What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?

Basit Öğe Kaydı
dc.contributor.authorKayikcioglu, Meral
dc.contributor.authorTokgozoglu, Lale
dc.contributor.authorDogan, Volkan
dc.contributor.authorCeyhan, Ceyhun
dc.contributor.authorTuncez, Abdullah
dc.contributor.authorKutlu, Merih
dc.contributor.authorOnrat, Ersel
dc.contributor.authorAlici, Gokhan
dc.contributor.authorAkbulut, Mehmet
dc.contributor.authorCelik, Ahmet
dc.contributor.authorYesilbursa, Dilek
dc.contributor.authorSahin, Tayfun
dc.contributor.authorSonmez, Alper
dc.contributor.authorOzdogan, Oner
dc.contributor.authorTemizhan, Ahmet
dc.contributor.authorKilic, Salih
dc.contributor.authorBayram, Fahri
dc.contributor.authorSabuncu, Tevfik
dc.contributor.authorCoskun, Fatma Yilmaz
dc.contributor.authorIldizli, Muge
dc.contributor.authorDurakoglugil, Emre
dc.contributor.authorKirilmaz, Bahadir
dc.contributor.authorYilmaz, Mehmet Birhan
dc.contributor.authorYigit, Zerrin
dc.contributor.authorYildirim, Aytul Belgi
dc.contributor.authorGedikli, Omer
dc.contributor.authorTopcu, Selim
dc.contributor.authorOguz, Aytekin
dc.contributor.authorDemir, Mesut
dc.contributor.authorYenercag, Mustafa
dc.contributor.authorYildirir, Aylin
dc.contributor.authorDemircan, Sabri
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorKaynar, Leyla Gul
dc.contributor.authorAktan, Melih
dc.contributor.authorDurmus, Rana Berru
dc.contributor.authorGokce, Cumali
dc.contributor.authorOzcebe, Osman Ilhami
dc.contributor.authorAkyol, Tulay Karaagac
dc.contributor.authorOkutan, Harika
dc.contributor.authorSag, Saim
dc.contributor.authorGul, Ozen Oz
dc.contributor.authorSalcioglu, Zafer
dc.contributor.authorAltunkeser, Bulent Behlul
dc.contributor.authorKuku, Irfan
dc.contributor.authorYasar, Hurriyet Yilmaz
dc.contributor.authorKurtoglu, Erdal
dc.contributor.authorKose, Melis Demir
dc.contributor.authorDemircioglu, Sinan
dc.contributor.authorPekkolay, Zafer
dc.contributor.authorIlhan, Osman
dc.contributor.authorCan, Levent H.
dc.date.accessioned2019-10-27T10:02:00Z
dc.date.available2019-10-27T10:02:00Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and aims: Familial hypercholesterolemia (FH) is a common genetic disease of high-level cholesterol leading to premature atherosclerosis. One of the key aspects to overcome FH burden is the generation of largescale reliable data in terms of registries. This manuscript underlines the important results of nation-wide Turkish FH registries (A-HIT1 and A-HIT2). Methods: A-HIT1 is a survey of homozygous FH patients undergoing low density lipoprotein (LDL) apheresis (LA). A-HIT2 is a registry of adult FH patients (homozygous and heterozygous) admitted to outpatient clinics. Both registries used clinical diagnosis of FH. Results: A-HIT1 evaluated 88 patients (27 +/- 11 years, 41 women) in 19 centers. All patients were receiving regular LA. There was a 7.37 +/- 7.1-year delay between diagnosis and initiation of LA. LDL-cholesterol levels reached the target only in 5 cases. Mean frequency of apheresis sessions was 19 +/- 13 days. None of the centers had a standardized approach for LA. Mean frequency of apheresis sessions was every 19 +/- 13 (7-90) days. Only 2 centers were aware of the target LDL levels. A-HIT2 enrolled 1071 FH patients (53 +/- 8 years, 606 women) from 31 outpatients clinics specialized in cardiology (27), internal medicine (1), and endocrinology (3); 96.4% were heterozygous. 459 patients were on statin treatment. LDL targets were attained in 23 patients (2.1% of the whole population, 5% receiving statin) on treatment. However, 66% of statin-receiving patients were on intense doses of statins. Awareness of FH was 9.5% in the whole patient population. Conclusions: The first nationwide FH registries revealed that FH is still undertreated even in specialized centers in Turkey. Additional effective treatment regiments are urgently needed.en_US
dc.description.sponsorshipTurkish Society of Cardiology; Aegerion; Amyrit; AmgenAmgen; PfizerPfizer; SanofiSanofi-Aventisen_US
dc.description.sponsorshipA-HIT1 and 2 registries are sponsored by the Turkish Society of Cardiology that receives funding from a variety of sources (including unrestricted research grants from Aegerion, Amyrit, Amgen, Pfizer, and Sanofi).en_US
dc.identifier.doi10.1016/j.atherosclerosis.2018.08.012en_US
dc.identifier.endpage346en_US
dc.identifier.issn0021-9150
dc.identifier.issn1879-1484
dc.identifier.pmid30270069en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage341en_US
dc.identifier.urihttps://doi.org/10.1016/j.atherosclerosis.2018.08.012
dc.identifier.urihttps://hdl.handle.net/11454/29934
dc.identifier.volume277en_US
dc.identifier.wosWOS:000445908000052en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofAtherosclerosisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFamilial hypercholesterolemiaen_US
dc.subjectTurkeyen_US
dc.subjectRegistryen_US
dc.titleWhat have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu